Vermillion, Inc. (VRML)
-NasdaqCM 3.08 0.00(0.00%) May 24, 3:59PM EDT|After Hours
:
3.08 0.00 (0.00%) May 24, 5:06PM EDT
| Prev Close: | 3.08 |
|---|
| Open: | 3.06 |
|---|
| Bid: | 2.07 x 200 |
|---|
| Ask: | 3.12 x 1000 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.16 |
|---|
| Next Earnings Date: | 12-Aug-13 |
|---|
| Day's Range: | 3.02 - 3.13 |
|---|
| 52wk Range: | 1.03 - 3.25 |
|---|
| Volume: | 220,470 |
|---|
| Avg Vol (3m): | 181,558 |
|---|
| Market Cap: | 46.86M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.53 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- VERMILLION, INC. Files SEC form 8-K, Other EventsEDGAR Online(Fri, May 24)
- VERMILLION, INC. FinancialsEDGAR Online Financials(Tue, May 21)
- Vermillion Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 15)
- Vermillion, Inc. Earnings Call scheduled for 4:30 pm ET todayCCBN(Wed, May 15)
- Vermillion Reports First Quarter 2013 ResultsPR Newswire(Wed, May 15)
- Emerging Biomarker Companies Redux: Positioned For Growthat Seeking Alpha(Wed, May 15)
- VERMILLION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, May 15)
- Q1 2013 Vermillion, Inc. Earnings Release - After Market CloseCCBN(Wed, May 15)
- VERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or ByEDGAR Online(Tue, May 14)
- Vermillion Announces Closing of Equity FinancingPR Newswire(Tue, May 14)
- Vermillion Earnings Preview: Can This Streak Continue?at Wall St. Cheat Sheet(Mon, May 13)
- VERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiEDGAR Online(Thu, May 9)
- Vermillion Announces Equity FinancingPR Newswire(Thu, May 9)
- Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and TreatmentPR Newswire(Wed, May 8)
- Detecting Investment Potential In Medical Diagnostics Companiesat Seeking Alpha(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 22.21 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.61 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.15 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Vermillion, Inc., together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients.
View More